齐拉西酮与利培酮治疗难治性精神分裂症对照研究

A Comparative Study on the efficacy of Ziprasidone with that of Risperidone in the Treatment of Treatment-resistant Schizophrenia

目的探讨齐拉西酮治疗难治性精神分裂症的疗效及安全性。方法将84例难治性精神分裂症患者随机分为研究组和对照组,分别给予齐拉西酮和利培酮治疗8周,采用PANSS量表和TESS量表评定疗效和不良反应。结果治辽前后齐拉西酮组PANSS减分率为40.08%,有效率为83.33%;利培酮组PANSS减分率为38.56%,有效率为76.19%,两者比较差异无显著性(P>0.05),齐拉西酮组未见严重的不良反应。结论齐拉西酮与利培酮治疗难治性精神分裂症疗效相当,齐拉西酮对认知功能的改善优于利培酮,但两者比较差异无显著性(P>0.05),齐拉西酮治疗难治性精神分裂症具有疗效好、副作用小,病人依从性好的特点。

Objective To evaluate the efficacy and safety of ziprasidone in the treatment of treatment-resistant schizophrenia. Methods A total of 84 patients with treatment-resistant schizophrenia were randomly assigned to Ahrasidone group and risperidone group for 8 weeks of treatment. The efficacy and side effects were measured with Positive and Negative Symptom Scale (PANSS) and Treatment Emergent Symptom Scale (TESS). Results There was no significant difference in efficacy between two groups. The reducing rates of...